Clinical Compound Bank
Access our patient-ready compounds with evidence of human target coverage and manageable tolerability.
Access compounds with optimised pharmacological properties for preclinical research to study pathways and mechanisms of disease biology.
Have a novel target idea or assay for a drug discovery project? Our diverse High Throughput Screening (HTS) compound library may help you advance or validate your idea.
New Molecule Profiling
Explore the properties and therapeutic potential of your novel compounds by leveraging our cheminformatic and screening technologies.
Offer and be rewarded for your innovative ideas and research expertise to help overcome difficult R&D barriers.
Are you looking to access preclinical data to further advance understanding of human disease and safety? We are providing access to data sets to enhance understanding of translation to human efficacy and safety.
Do you have an idea, technology or suggestion outside of these categories? We are still welcoming proposals, so please get in touch.
Leading the Way in Open Innovation
clinical and preclinical projects in progress
compounds available from our screening library
R&D Challenges awarded to date
We are committed to driving scientific advances in small molecules, oligonucleotides and other emerging technology platforms to push the boundaries of medical science.
Why collaborate through Open Innovation?
Beyond the usual research partnerships – let's push the boundaries of science together
AstraZeneca has spent decades creating unique enabling tools and technologies of interest to the scientific community of investigators. These include optimised compounds with extensive data packages, high throughput screening libraries and facilities, cheminformatics and other in silico analytics, and drug R&D knowhow, expertise and experience. At the same time, academic, research foundation and biotech investigators have been developing insights, tools, technologies, platforms, resources and facilities that complement those of AstraZeneca. Examples include disease pathophysiology and patient care insights, assay, biomarker and imaging technologies, and specialised facilities.
By bringing all of this together through partnering, we can test hypotheses that may otherwise not be possible. Sharing ideas and enabling scientific innovation to cross boundaries between academia, industry, government and non-profit organisations will help us translate innovative ideas into scientific breakthroughs and potential new medicines more quickly and effectively.
At AstraZeneca, we have great scientists doing truly ground-breaking research. But in order to speed up the delivery of the next generation of medicines, we also need to access the best science outside our labs. We are always looking for new ways of working with academic or industry researchers who share our passion for advancing the science and helping patients with unmet medical needs.
Every day, we’re pushing the boundaries of science - in our own laboratories and with our collaboration partners. The way we work with our research partners is open, innovative and science-focused.
But don’t take our word for it. Hear what our partners around the world have to say about working with AstraZeneca.
In 2011, a novel agreement between the Medical Research Council (MRC) and AstraZeneca gave academic researchers across the UK unprecedented access to 22 of our clinical and preclinical compounds.
These compounds had stalled in early testing, often because they didn’t prove effective against the original target. But they may still be useful against other diseases. And because the compounds have already undergone some preliminary development, any new treatments arising from the research could reach patients faster. Fifteen studies are currently underway covering respiratory illness, muscular dystrophies, bone disease and various mental health conditions.
AstraZeneca featured news
Finding Harmony in PD-L1 Testing
Members of the durvalumab diagnostic team recently travelled to the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, to present our industry-leading research on programmed cell death ligand-1 (PD-L1) testing.1
My lung cancer journey
LabTalk blog post by Dr Denny Clifford - “Early in my career as a practicing Pulmonary and Critical Care specialist I was fortunate to be a Principal Investigator on an AstraZeneca study, which led to a long relationship investigating new pharmaceuticals in the Respiratory field. In my 33 years as a practicing doctor I have diagnosed over 800 lung cancers, and dedicated my time to providing patients with the best possible care.”
Joining forces with academia to discover novel chemistry approaches
We have been partnering with the Max-Planck Society and consortium companies for several years. In 2014, we established a chemistry ‘satellite unit’ for cardiovascular and metabolic diseases at the Max Planck Institute of Molecular Physiology in Dortmund, Germany. Here, AstraZeneca scientists are working side-by-side with academic researchers to study new modalities chemistry. This novel strategic alliance aims to discover innovative approaches to drug discovery by combining the strengths of industry and academia. Our focus is on novel chemistry and chemical biology in areas of new modality chemistry such as stabilised peptides, macrocycles and conjugation chemistry.
Lung Cancer Awareness Month: Spreading the Word about Scientific Advances
November is Lung Cancer Awareness Month; an important occasion when we can pause to reflect on valuable diagnostic and treatment advances in our journey to improving cancer outcomes. These scientific discovery milestones continue to excite me, along with the wider scientific community, and provide hope to patients and their loved ones.
Novel pre-clinical brain metastases models show good translation to clinical setting
For the first time our scientists have developed a suite of pre-clinical models to evaluate brain penetration of small molecule inhibitors and have shown their translatability in the clinical setting.
Harnessing personalised healthcare to identify novel therapeutic targets for Chronic Kidney Disease (CKD) patients
Each November, more than 13,000 leading nephrologists and other medical and scientific professionals from around the world present and discuss the latest advances and challenges in kidney research and treatment at the American Society of Nephrology Kidney Week. This year, with a steadily growing presence, AstraZeneca is presenting five abstracts from our early science research teams alone that unveil new evidence for novel, potential chronic kidney disease (CKD) drug targets that leverage our personalised healthcare approach.